Related resources
Search for item elsewhere
University researcher(s)
Academic department(s)
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma.
Clamp A, Blackhall FH, Vasey P, Soukop M, Coleman R, Halbert G, Robson L, Jayson G-
Br J Cancer. 2003;89( 7):1152-4.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Use our list of Related resources to find this item elsewhere. Alternatively, request a copy from the Library's Document supply service.
Abstract
Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia.
Keyword(s)
Adult; Aged; Disease Progression; Enzyme Activation; Female; Humans; Infusions, Intravenous; Middle Aged; Treatment Outcome; administration & dosage: Antineoplastic Agents; administration & dosage: Lactones; drug therapy: Neoplasm Recurrence, Local; drug therapy: Neoplasms, Glandular and Epithelial; drug therapy: Ovarian Neoplasms